Adjuvanted shingles subunit vaccine likely more cost-effective

Adjuvanted shingles subunit vaccine likely more cost-effective
(HealthDay)—The new adjuvanted herpes zoster subunit vaccine (HZ/su) is cost-effective compared with the currently recommended live attenuated herpes zoster vaccine (ZVL), according to a study published online Jan. 2 in JAMA Internal Medicine.

Phuc Le, Ph.D., M.P.H., and Michael B. Rothberg, M.D., M.P.H., both from the Cleveland Clinic, assessed the cost-effectiveness of HZ/su among immunocompetent adults aged 60 years or older. The model included scenarios for no vaccination, ZVL (single dose) , and HZ/su (two-dose series) vaccine administered at different ages.

Based on data, the researchers found that at a price of $280 per the two-dose series, HZ/su was more effective and less expensive than ZVL at all ages. Compared with no vaccination, the incremental cost-effectiveness ratios ranged from $20,038 to $30,084 per quality-adjusted life-year (QALY), depending on vaccination age. The findings were insensitive to variation other than in vaccine price and certain combinations of low adherence rate with a second dose and low efficacy of a single dose of HZ/su. HZ/su had lower overall costs than ZVL (at the current ZVL price of $213 per dose) up to a price of $350 per two-dose series.

"Under conservative assumptions, at a price of $280 per ($140 per dose), HZ/su would cost less than ZVL and has a high probability of offering good value," the authors write.


Explore further

Herpes zoster vaccine not cost-effective in adults aged 50 years

More information: Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
Journal information: JAMA Internal Medicine

Copyright © 2018 HealthDay. All rights reserved.

Citation: Adjuvanted shingles subunit vaccine likely more cost-effective (2018, January 8) retrieved 20 June 2019 from https://medicalxpress.com/news/2018-01-adjuvanted-shingles-subunit-vaccine-cost-effective.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
2 shares

Feedback to editors

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more